The burgeoning field of weight management has witnessed remarkable advancements with the emergence of dual GLP-3 receptor agonists, notably Retatrutide and Trizepatide. These innovative therapies represent a significant departure from traditional GLP-3 receptor agonists, exhibiting superior efficacy in promoting meaningful weight reduction and impr

Emerging in the field of obesity management, retatrutide is a different strategy. Beyond many current medications, retatrutide operates as a double agonist, concurrently affecting both glucagon-like peptide-1 (GLP-1) and glucose-responsive insulinotropic substance (GIP) receptors. This dual engagement encourages several beneficial effects, like imp